In the allogeneic approach, a universal iPSC line is used to generate cells and tissues needed for restoring normal biological function in patients.
These cells lines are engineered to be protected from being attacked by the patient’s immune system, allowing rapid and cost-effective treatment of currently incurable diseases while harnessing the revolutionary potential of cellular therapy.
Genomic and biological studies confirm suitability for developing universal cell banks
Cells are isolated from a small blood draw from the healthy donor
Healthy donor’s blood cells are reprogrammed into iPSCs using the “Yamanaka” factors
Healthy iPSCs are engineered to enable immune evasion and universal application in all patients
Universal iPSCs are differentiated into disease-specific cell types and tissues
Healthy universal cells and tissues are transplanted into patients